

# At the pulse of heart diseases

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunction. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

## Key facts



Founded 2016 and located in Hanover, Germany



Addressing cardiac diseases with ncRNAs



Broad proprietary platform



Series A: € 15M  
Series B: € 64M




Lead candidate with blockbuster potential




Experienced management team


# Technology



Diseased cardiac tissue



Cardior's treatment



Cardiac tissue normalization

Cardior's strong foundation for growth and innovation is based on non-coding RNAs (ncRNAs) that orchestrate fundamental cellular cardiac processes.

Targeting ncRNAs by Cardior's innovative therapeutics serve as a disease curating approach by triggering a concerted therapeutic effect against key hallmarks of heart disease, including cardiac remodeling processes such as pathological hypertrophy, impaired contractility and fibrosis.

From the company's growing pipeline of product compounds, the lead candidate demonstrates safety, tolerability, strong target engagement, initial efficacy and is currently being evaluated in a Phase 2 clinical trial in heart failure patients (NCT05350969).



Signaling pathways



RNA




RNA bound by Cardior's oligonucleotide

## Key Publications



# Pipeline



Our lead candidate CDR132L is an inhibitor directed against miRNA132, designed to halt and reverse the development of detrimental cardiac remodeling. As a therapeutic candidate, CDR132L has several distinguishing features:

- **CDR132L** selectively blocks aberrant miRNA132 levels contributing to improved cardiac systolic and diastolic function in patients
- **CDR132L** has the potential to prolong the patient's life span as well as improve quality of life
- **CDR132L** is a highly stable watersoluble oligonucleotide formulated for parenteral or subcutaneous application

## The advantages of the Cardior platform



Based on world-leading expertise in the therapeutic modulation of RNAs through synthetic oligonucleotides



Highly stable and effective RNA therapies resulting from a proprietary discovery engine



Pre-clinical proof-of-concept demonstrating the potential of the approach and first clinical evaluation completed



Deep understanding of the complex interplay of multiple disease-causing mechanisms and the role of ncRNAs



Effective target modulation and targeted delivery into the heart achieved



Successful scale up of a fast and cost-efficient GMP grade manufacturing

## Management Team

**Claudia Ulbrich, MD**  
CEO & Co-Founder

**Prof. Thomas Thum, MD**  
CSO/CMO & Founder

## Board

**Claus Andersson**  
PhD

**Simone Botti**  
PhD

**Christoph Broja**

**Martin Crook**  
PhD

**Luc Debruyne**

**Ulrich Granzer**  
PhD

**Russell Greig**  
PhD, Chairman

**Markus Hosang**  
PhD, Vice-chairman

**Orly Vardeny**  
PharmD, Permanent Guest

## Scientific Advisory Board

**Prof. Johann Bauersachs**  
MD

**Prof. Javed Butler**  
MD

**Prof. Perry Elliott**  
MD

**Gerasimos Filippatos**  
MD, PhD

**Arthur A. Levin**  
PhD

**Prof. Douglas L. Mann**  
MD

**Prof. Scott Solomon**  
MD

**Barry Ticho**  
MD, PhD

**Prof. Faiez Zannad**  
MD, PhD

## Investors

**BioMedPartners**

 **Bristol Myers Squibb**

**COPARION**



**inkef capital**

**sunstone**  
LIFE SCIENCE VENTURES

**Cardior Pharmaceuticals GmbH**  
Hollerithallee 20  
30419 Hannover

Email  
info@cardior.de

Phone  
+49 511 3385 9930

Find us on social media

